title: Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2.
abstract: The amino terminus of the human papillomavirus minor capsid protein L2 contains a major cross-neutralizing epitope that provides the basis for the development of a broadly protective HPV vaccine. This attainable broad protection would eliminate one of the major drawbacks of the commercial L1-based prophylactic vaccines. In this study, we asked whether there are natural variants of the L2 cross-neutralizing epitope and if these variants provide means for immune escape from vaccine-induced anti-L2 antibodies. For this, we isolated in silico and in vitro, a total of 477 L2 sequences of HPV types 16, 18, 31, 45, 51, 52 and 58. We identified natural L2 epitope variants for HPV 18, 31, 45 and 51. To determine whether these variants escape L2-directed neutralization, we generated pseudovirions encompassing the natural variants and tested these in an in vitro neutralization assay using monoclonal and polyclonal antibodies. Our results indicate that natural variants of the L2 major neutralizing epitope are frequent among two different study populations from Germany and Mongolia and in the GenBank database. Of two identified HPV 31 L2 single amino acid variants, one could be neutralized well, while the other variant was neutralized very poorly. We also observed that single amino acid variants of HPV 18 and 45 are neutralized well while a HPV 18 double variant was neutralized at significantly lower rates, indicating that L2 variants have to be accounted for when developing HPV L2-based prophylactic vaccines.
authors.affiliation: Deutsches Krebsforschungszentrum Heidelberg, Germany.
authors.forename: Hanna
authors.initials: H
authors.lastname: Seitz
authors.forename: Markus
authors.initials: M
authors.lastname: Schmitt
authors.forename: Gerd
authors.initials: G
authors.lastname: Böhmer
authors.forename: Annette
authors.initials: A
authors.lastname: Kopp-Schneider
authors.forename: Martin
authors.initials: M
authors.lastname: Müller
mesh_terms: D000595:Amino Acid Sequence; D019943:Amino Acid Substitution; D057134:Antibodies, Neutralizing / Q000276:immunology; D000914:Antibodies, Viral / Q000276:immunology*; D002213:Capsid / Q000276:immunology*; D036022:Capsid Proteins / Q000235:genetics / Q000276:immunology*; D000939:Epitopes; D014644:Genetic Variation; D006801:Humans; D008969:Molecular Sequence Data; D009856:Oncogene Proteins, Viral / Q000235:genetics / Q000276:immunology*; D027383:Papillomaviridae / Q000235:genetics / Q000276:immunology*; D030361:Papillomavirus Infections / Q000276:immunology / Q000517:prevention & control / Q000821:virology; D053918:Papillomavirus Vaccines / Q000276:immunology; D016415:Sequence Alignment
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D036022:Capsid Proteins; D000939:Epitopes; D009856:Oncogene Proteins, Viral; D053918:Papillomavirus Vaccines